NovoCure Limited
14.68USD
-0.4200 (-2.78%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on NVCR.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 184 | 174 | 174 | 167 | 159 | 155 | 161 | 155 |
| Cost of Revenue | 41 | 39 | 42 | 45 | 41 | 39 | 33 | 35 |
| Gross Profit | 142 | 135 | 132 | 122 | 117 | 116 | 128 | 120 |
| Operating Income | -11 | -67 | -40 | -36 | -40 | -38 | -63 | -32 |
| Net Income | -16 | -71 | -24 | -37 | -40 | -34 | -66 | -31 |
| EPS (Diluted) | -$0.13 | -$0.62 | -$0.22 | -$0.33 | -$0.36 | -$0.31 | -$0.61 | -$0.28 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)